A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was: which is the best tissue valve for use in the pulmonary position, late after previous repair of tetralogy of Fallot? Altogether 141 papers were found using the reported search, of which 13 represented the best evidence to answer the clinical question. In addition to this, 1 paper was found by searching the reference lists of the relevant papers. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We conclude from the best evidence available that homograft valves function well in the pulmonary position late after Tetralogy of Fallot (TOF) repair. This is particularly evident in the larger studies where the patients were only treated with homografts. It has been suggested that Homografts are better than xenografts and this has not been statistically shown. Two articles have suggested that xenografts outperform homografts however, in both studies these results were not statistically significant. Furthermore, early indications suggest that porcine valves may be better than bovine pericardial valves but a better longer term follow-up is certainly required to demonstrate this. It is important to realize also that when comparing the effectiveness of these valves in the pulmonary position, one cannot ignore confounding factors. The most important of these include timing of operation, age of patient, valve size, immunological factors, operative complexity and also postoperative valvular gradients. The timing of these operations has always been an area of great controversy illustrated by varied guidelines. There is no general consensus regarding whether there is even a role of pulmonary valve replacement late after TOF repair. Further weakening any conclusions that may be drawn based on current best evidence is the lack of strong follow-up data (transvalvular gradients and right ventricular (RV) volumetric data). New research is required with comparisons using objective clinical parameters in order to more effectively answer our clinical question.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] 
THREE-PART QUESTION
In patients who have had previous [Tetralogy of Fallot repair] 
CLINICAL SCENARIO
A 23-year old female who had previously undergone a repair of tetralogy of Fallot (TOF) at the age of 1 year re-presented to the adult congenital cardiology service with NYHA class II symptoms of breathlessness. Investigations with echocardiogram and cardiac MRI demonstrated severe pulmonary regurgitation, mild tricuspid regurgitation and right ventricle (RV) dysfunction, with a significantly dilated right ventricular end-diastolic volume index of 175 ml/m 2 . The case was discussed in the multidisciplinary meeting and put forward for repeat cardiac surgery to replace her pulmonary valve.
SEARCH STRATEGY
MEDLINE 1950 to January 2013 using PubMed interface.
Pulmonary valve replacement and (tetralogy of Fallot or tetralogy of Fallot/surgery) and (bioprosthesis or xenograft or porcine or bovine pericardial or heart valve prosthesis) not (transcatheter or percutaneous or mechanical).
RESULTS

Concerning pulmonary valve replacement (PVR) late after
Tetralogy of Fallot (TOF) repair, there were 13 studies comprising 1102 patients. The majority of the papers were conducted in retrospect. There was one prospective study conducted by Oosterhof et al. [2] . Five papers contained a small sample size (n < 45), and thus, results presented in these studies generally failed to reach statistical significance [3] [4] [5] [6] [7] . Of the smaller studies listed above, porcine and bovine xenografts and cryopreserved homografts were used in varying frequency. Discigil et al. [3] and Warner et al. [4] concluded that homografts outperformed heterografts. Shiokawa et al. [5] , in a cohort study, found no difference between homografts and heterografts in 19 patients over a 20-year follow-up period.
Vliegen et al. [6] performed a retrospective cardiac MRI study of 26 patients who had undergone a PVR late after TOF repair. They concluded that the use of a homograft is safe and associated with excellent haemodynamic and clinical results.
Van Straten et al. [7] conducted a study comprising 25 patients undergoing PVR late after TOF repair, all with homografts. Using cardiac MR scanning at set times preoperatively and during follow-up, they found that PVR with homografts improves RV function significantly. They did, however, report a very high recurrence of pulmonary regurgitation (PR) after PVR at a median follow-up time of 18.6 months (range 17.2-34.9 months).
Kanter et al. [8] performed a retrospective cohort study comparing the use of porcine xenograft valves and homografts in 93 patients who had 100 PVR's late after right ventricular outflow tract (RVOT) obstruction repair. In terms of freedom from reoperation and freedom from valvular dysfunction, they suggested that porcine valves may be favourable; however, this failed to reach statistical significance.
Jang et al. [9] performed a retrospective study of the outcomes of 131 PVR's after TOF repairs between 2001 and 2010. Three different valves were used: Medtronic Hancock II (n = 58), Carpentier-Edwards Perimount (n = 49) and St. Jude Biocor (n = 35). The Carpentier-Edwards Perimount valves had a higher rate of reoperation compared with the St. Jude Biocor and the Medtronic Hancock II valves, but this failed to reach statistical significance. The Carpentier-Edwards valve was a risk factor for reoperation in the univariate analysis but not in the multivariate analysis.
Oosterhof et al. [10] retrospectively analysed 158 TOF patients who underwent subsequent PVR with a homograft. The results showed that there was a very high rate of freedom from adverse events at 10 years. At 10 years 53% of patients had valve dysfunction; however, only 26.9% went onto reoperation.
Yemets et al. [11] , in a retrospective study of 85 patients who had an elective PVR late after TOF repair, showed that there was no significant difference between bovine pericardial and porcine valves. They suggested, however, that longer term follow-up would likely reveal porcine valves to be more durable, when looking at the initial results.
Oosterhof et al. [2] conducted a nationwide, prospective followup study between 1993 and 2006. During this time, 71 adult patients with previously repaired tetralogy of Fallot underwent subsequent PVR's. The outcomes suggested that the use of homografts in the pulmonary position after TOF repair is effective in improving NYHA classification (P < 0.05) while maintaining low mortality. The rate of freedom from reoperation was found to be 95.8%, this however was during the short follow-up time, median of 1.6 (range 0.9-5.2) years.
Lim et al. [12] analysed the clinical course of 58 consecutive patients (38 males and 20 females) who underwent PVR for PR after previous repair of tetralogy of Fallot or Fallot-type double outlet right ventricle from January 1993 to July 2002. This is a single-centre, retrospective study comparing preoperative and postoperative echocardiograms. The main outcome was that porcine valves may be more durable than other tissue valves; however, this failed to reach statistical significance.
Therrien et al. [13] designed a study involving 70 consecutive PVRs after TOF repair. It showed that PVR using xenografts was very haemodynamically advantageous initially and at latest follow-up.
Sherptong et al. [14] prospectively conducted a study involving multiple centres. It included 90 patients undergoing PVR's late after TOF repair. All patients had homografts implanted. Early mortality was 0% and only 2.2% during a mean follow-up time of 5.5 ± 3.5 years. There was a significant rate of adverse clinical events, but low enough to be deemed acceptable (14.4%). Freedom from reoperation was low (94.4%).
Finally, Harrild et al. [15] conducted a case-control study comparing patients who had TOF and a late PVR with patients who did not have a PVR. Overall event-free survival at 5 and 10 years was 80 and 41%, respectively. They did not demonstrate any benefit in event-free survival of having a PVR late after TOF. The dimensions of the RV may have improved by having a PVR.
CLINICAL BOTTOM LINE
We conclude from the best evidence available that homograft valves function well in the pulmonary position late after TOF repair. This is particularly evident in the larger studies where the patients were only treated with homografts [10, 14] . It has been suggested that Homografts are better than xenografts, but this has not been statistically shown [3, 8] . Two articles have suggested that xenografts outperform homografts [4, 12] ; however, in both studies these results were not statistically significant. Furthermore, early indications suggest that porcine valves may be better than bovine pericardial valves [9, 11] , but a better longer term followup is certainly required to demonstrate this.
It is important to realize that when comparing the effectiveness of these valves in the pulmonary position, one cannot ignore confounding factors. The most important of these include timing of operation, age of patient, valve size, immunological factors, operative complexity and also postoperative valvular gradients. The timing of these operations has always been an area of great controversy illustrated by varied guidelines. There is no general consensus regarding whether there is even a role of PVR late after TOF repair [15] in certain patients.
Further weakening any conclusions that may be drawn based on current best evidence is the lack of strong follow-up data (transvalvular gradients and RV volumetric data). New research is required with comparisons using objective clinical parameters in order to more effectively answer our clinical question. This study included 100 PVRs in 93 children after RVOT obstruction
BEST EVIDENCE TOPIC
The majority of the initial diagnoses were TOF (n = 62). Others include critical pulmonary stenosis and pulmonary atresia
Valves used were homografts (n = 62) and porcine xenografts (n = 38)
Age at PVR was 4.5 months to 27.9 years (median 9.5 years)
Mean follow-up was 4.9 years (5 months to 12.4 years)
Perioperative mortality Porcine valve: 1 (1%) Homograft: 0 (0%) P = not significant
The homograft valves were more susceptible to postoperative stenosis and more frequently required percutaneous intervention and reoperation at 1 year
The authors recommend that xenografts remain second line after homografts in paediatric recipients
Freedom from reoperation at 8 years Negative event-free survival 5 years: 88% 10 years: 78% The grafts used were homografts (n = 31) and bovine pericardial valves (n = 5)
Continued
The patients were aged 15.2 ± 9. The valves used for PVR were porcine heterografts prostheses (n = 25), bovine pericardial heterografts (n = 8) and homograft prostheses (n = 9) 
BEST EVIDENCE TOPIC
I read with great interest the paper by Abbas et al. regarding the best tissue valve substitute for pulmonary valve replacement in the setting of previous repair of tetralogy of Fallot [1] . They included in their search strategy stented bioprostheses and homografts as substitutes for pulmonary valve replacement. I would like to add a brief comment on the evolving role of transcatheter pulmonary valve implantation (TPVI) in such a subset of patients.
Improvements in imaging, catheter technology, and stent design have made transcatheter replacement of the pulmonic valve a clinical reality. The Melody valve (Medtronic Inc, Minneapolis, MN, USA) was introduced in clinical practice in 2000 as a transcatheter alternative to pulmonary valve replacement for right ventricle-to-pulmonary artery outflow tract conduit dysfunction. The relative short lifespan of such conduits used in repairs of complicated congenital heart defects makes future surgical intervention unavoidable. TPVI offers an attractive alternative to surgery in patients with right outflow conduit dysfunction. Numerous studies have shown that the Melody valve is an accepted alternative to surgical pulmonary valve replacement in patient with right ventricular tract dysfunction with conduit less than 22 mm in diameter. Recently, Boudjemline et al. [2] found that patients with larger dysfunctional conduit with heamodynamically significant regurgitation can be treated successfully with the Melody valve. They implanted this valve in 13 patients with a previous history of surgically repaired tetralogy of Fallot using the Russian dolls technique and/or the pulmonary artery jailing technique, both prestenting techniques intended to prepare the large conduit to contain the Melody valve.
One major drawback of the Melody valve is the high incidence of stent fracture leading to valve failure in more than 25% of cases [3] . The COMPASSION trial [4] is the first study to assess the safety and efficacy of the Sapien Pulmonic Transcatheter Heart Valve (THV) (Edwards Lifesciences LLC, Irvine, CA, USA) in this patient population. There were 36 patients enrolled in this prospective, non-randomized multicentre study. Pre-stenting of the conduit with a bare metal stent was accomplished in all cases; this provides a secure landing zone for the Sapien THV valve. The COMPASSION trial demonstrated that this valve yielded excellent short-term functionality up to 6 months after the implantation in the failure conduit (regurgitation with or without stenosis). There was no stent fracture in this cohort. Another advantage of the Sapien Pulmonic Valve is the availability in different and larger diameters than the Melody valve which is available only in one size (18 mm in diameter).
TPVI is gaining increasing recognition as a less invasive alternative to surgical pulmonary valve replacement [5] , however long-term results are lacking and further data are necessary to validate this interesting approach to right ventricular outflow tract dysfunction.
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